BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 4,720.00
-50.00 (-1.05%)
Last updated: Jun 4, 2026, 11:00 AM KST
BioNote Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 122,445 | 118,324 | 102,780 | 90,081 | 479,657 | 622,355 |
Other Revenue | - | - | - | 0 | -0 | -0 |
| 122,445 | 118,324 | 102,780 | 90,081 | 479,657 | 622,355 | |
Revenue Growth (YoY) | 15.60% | 15.12% | 14.10% | -81.22% | -22.93% | -1.45% |
Cost of Revenue | 52,842 | 52,648 | 51,807 | 101,739 | 139,186 | 110,352 |
Gross Profit | 69,603 | 65,675 | 50,973 | -11,659 | 340,471 | 512,003 |
Selling, General & Admin | 29,369 | 28,199 | 22,868 | 22,787 | 31,519 | 24,340 |
Research & Development | 17,720 | 16,841 | 13,577 | 13,405 | 16,138 | 11,300 |
Amortization of Goodwill & Intangibles | 1,010 | 1,011 | 1,005 | 858.1 | 174.51 | 44.15 |
Other Operating Expenses | 168.48 | 178.72 | 265.78 | 168.12 | 176.92 | 345.29 |
Operating Expenses | 51,130 | 48,867 | 38,756 | 35,510 | 45,062 | 43,255 |
Operating Income | 18,472 | 16,809 | 12,218 | -47,168 | 295,410 | 468,748 |
Interest Expense | -241.08 | -287.12 | -233.55 | -602.82 | -84.44 | -44.25 |
Interest & Investment Income | 14,790 | 14,697 | 20,059 | 24,630 | 9,715 | 873.63 |
Earnings From Equity Investments | - | - | 18,910 | - | -147,264 | - |
Currency Exchange Gain (Loss) | 14,190 | -6,345 | 40,603 | 10,164 | 24,512 | 24,159 |
Other Non Operating Income (Expenses) | 81.64 | 40.43 | 1,096 | 420.84 | -296.63 | -123.11 |
EBT Excluding Unusual Items | 47,292 | 24,914 | 92,653 | -12,556 | 181,992 | 493,612 |
Gain (Loss) on Sale of Investments | -97,642 | -110,811 | -14,511 | -88,791 | 219,374 | 376,239 |
Gain (Loss) on Sale of Assets | -1,681 | -1,671 | 20.25 | 265.2 | 13,412 | 33.39 |
Asset Writedown | - | - | -4,835 | -8,409 | - | - |
Pretax Income | -52,031 | -87,568 | 73,327 | -109,491 | 414,778 | 869,885 |
Income Tax Expense | -1,804 | -70.26 | 18,065 | -88,994 | 106,980 | 193,284 |
Net Income | -50,226 | -87,498 | 55,261 | -20,497 | 307,798 | 676,601 |
Net Income to Common | -50,226 | -87,498 | 55,261 | -20,497 | 307,798 | 676,601 |
Net Income Growth | - | - | - | - | -54.51% | 28.09% |
Shares Outstanding (Basic) | 101 | 101 | 102 | 102 | 94 | 94 |
Shares Outstanding (Diluted) | 101 | 101 | 102 | 102 | 94 | 94 |
Shares Change (YoY) | -0.54% | -0.73% | -0.02% | 8.16% | 0.64% | 0.14% |
EPS (Basic) | -496.95 | -865.27 | 542.00 | -200.99 | 3277.21 | 7232.04 |
EPS (Diluted) | -496.95 | -865.27 | 542.00 | -201.00 | 3264.00 | 7222.00 |
EPS Growth | - | - | - | - | -54.81% | 27.91% |
Free Cash Flow | 18,482 | 6,270 | 47,454 | -8,156 | 206,834 | 485,966 |
Free Cash Flow Per Share | 182.86 | 61.95 | 465.43 | -79.98 | 2193.65 | 5186.94 |
Gross Margin | 56.84% | 55.51% | 49.59% | -12.94% | 70.98% | 82.27% |
Operating Margin | 15.09% | 14.21% | 11.89% | -52.36% | 61.59% | 75.32% |
Profit Margin | -41.02% | -73.95% | 53.77% | -22.75% | 64.17% | 108.72% |
Free Cash Flow Margin | 15.09% | 5.30% | 46.17% | -9.05% | 43.12% | 78.09% |
EBITDA | 28,050 | 26,036 | 20,404 | -38,962 | 301,861 | 472,854 |
EBITDA Margin | 22.91% | 22.00% | 19.85% | -43.25% | 62.93% | 75.98% |
D&A For EBITDA | 9,578 | 9,227 | 8,186 | 8,206 | 6,451 | 4,106 |
EBIT | 18,472 | 16,809 | 12,218 | -47,168 | 295,410 | 468,748 |
EBIT Margin | 15.09% | 14.21% | 11.89% | -52.36% | 61.59% | 75.32% |
Effective Tax Rate | - | - | 24.64% | - | 25.79% | 22.22% |
Advertising Expenses | - | 3,687 | 2,422 | 2,414 | 2,332 | 1,063 |